Literature DB >> 31389805

Indications, contraindications, and safety aspects of procedural sedation.

Maartje van Haperen1, Benedikt Preckel, Susanne Eberl.   

Abstract

PURPOSE OF REVIEW: There is a steadily increasing demand for procedural sedation outside the operating room, frequently performed in comorbid high-risk adult patients. This review evaluates the feasibility and advantages of sedation vs. general anesthesia for some of these new procedures. RECENT
FINDINGS: Generally, sedation performed by experienced staff is safe. Although for some endoscopic or transcatheter interventions sedation is feasible, results of the intervention might be improved when performed under general anesthesia. For elected procedures like intra-arterial treatment after acute ischemic stroke, avoiding general anesthesia and sedation at all might be the optimal treatment.
SUMMARY: Anesthesiologists are facing continuously new indications for procedural sedation in sometimes sophisticated diagnostic or therapeutic procedures. Timely availability of anesthesia staff will mainly influence who is performing sedation, anesthesia or nonanesthesia personal. While the number of absolute contraindications for sedation decreased to almost zero, relative contraindications are becoming more relevant and should be tailored to the individual procedure and patient.

Entities:  

Mesh:

Year:  2019        PMID: 31389805     DOI: 10.1097/ACO.0000000000000777

Source DB:  PubMed          Journal:  Curr Opin Anaesthesiol        ISSN: 0952-7907            Impact factor:   2.706


  1 in total

1.  Clinical outcomes of patients undergoing percutaneous left atrial appendage occlusion in general anaesthesia or conscious sedation: data from the prospective global Amplatzer Amulet Occluder Observational Study.

Authors:  Kerstin Piayda; Katharina Hellhammer; Jens Erik Nielsen-Kudsk; Boris Schmidt; Patrizio Mazzone; Sergio Berti; Sven Fischer; Juha Lund; Matteo Montorfano; Paolo Della Bella; Ryan Gage; Tobias Zeus
Journal:  BMJ Open       Date:  2021-03-24       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.